Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback